You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In a pair of recent studies, Crescendo put forth new clinical utility data and an age and adiposity-adjusted model for its Vectra DA rheumatoid arthritis test.
OraSure CEO Stephen Tang discussed the firm's plans for international expansion, while Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform.
Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.
The firm's CEO told investors at the JP Morgan Healthcare Conference that in addition to driving growth of its sepsis test in the US, Accelerate is eyeing expansion into China.
Using tech developed by CEO Omid Farokhzad, the startup is building tests for cancer and neurological diseases, the first of which it aims to launch in 2021.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
The firm plans to offer more than 13 million shares of its common stock at $.225 per share. The offering will close on or about Jan. 14.
After a successful pilot that recruited 1,000 patients, NorthShore will now engage 10,000 people to receive Color's genomic testing in their primary care.
eTrueNorth and Southeastern Grocers are partnering to launch the labs. Southeastern's grocery stores will also participate in eTrueNorth's biometric data program.
In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.